Infective endocarditis is an infection of the endocardial surface of the heart including infections of the large thoracic vessels and intracardiac foreign bodies characterized by the presence of vegetation which is a nidus for microorganism invasion.
Native valve endocarditis is an endovascular microbial infection of native heart valves that may be local including valvular and perivalvular destruction or distal due to detachment of septic vegetations with embolism, metastatic infection and septicemia.
Prosthetic valve endocarditis is an endovascular microbial infection of prosthetic heart valves and may be classified as an infection likely to have been acquired perioperatively and thus being nosocomial or likely to have been community-acquired.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.